Home » Stocks » STRO

Sutro Biopharma, Inc. (STRO)

Stock Price: $26.64 USD 0.71 (2.74%)
Updated Jan 15, 2021 1:05 PM EST - Market open
Market Cap 1.18B
Revenue (ttm) 45.75M
Net Income (ttm) 12.63M
Shares Out 35.88M
EPS (ttm) 0.44
PE Ratio 60.41
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $26.64
Previous Close $25.93
Change ($) 0.71
Change (%) 2.74%
Day's Open 25.75
Day's Range 25.73 - 27.82
Day's Volume 688,022
52-Week Range 6.19 - 27.82

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 1 week ago

Sutro is a leader in CFPS and has major collaborations to prove it. Its early data is a lethal late line cancer is very promising.

PRNewsWire - 1 week ago

SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicatio...

PRNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 8, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicatio...

Benzinga - 1 month ago

iBio (NYSE: IBIO) shares are trading lower on Tuesday after the company announced a common stock offering. iBio's main area of business is plant-based protein expression technologies for vacci...

Other stocks mentioned: CMD, IBIO
PRNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 7, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicatio...

PRNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 7, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicatio...

The Motley Fool - 1 month ago

One of the company's pipeline treatments shows encouraging results in ovarian cancer patients.

Benzinga - 1 month ago

Sutro Biopharma (NASDAQ: STRO) shares are trading higher on Friday after the company announced interim data on its STRO-002 Phase 1 dose-escalation study for patients with ovarian cancer. Sutr...

Other stocks mentioned: BCRX, MRNA, LLY
InvestorPlace - 1 month ago

Sutro Biopharma (STRO) is on the rise Friday with heavy trading of STRO stock despite the company not announcing anything new today. The post Sutro Biopharma: 7 Things for STRO Stock Investors...

24/7 Wall Street - 1 month ago

Sutro Biopharma Inc. (NASDAQ: STRO) made a huge gain to close out the week after the firm provided an update from its ongoing dose-escalation in its ovarian cancer trial.

PRNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 3, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicatio...

PRNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicati...

PRNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicati...

PRNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development, and manufacturing company, today announced that C...

PRNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 5, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicatio...

Seeking Alpha - 3 months ago

Week 39 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

Other stocks mentioned: AAPL, AXGT, AXP, JPM, KO, MCD, MRK, NKE, PFE, WMT, SIOX
PRNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 /PRNewswire/ -- Sutro Biopharma, Inc.

PRNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 2, 2020 /PRNewswire/ -- Sutro Biopharma, Inc.

PRNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 25, 2020 /PRNewswire/ -- Sutro Biopharma, Inc.

PRNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 /PRNewswire/ -- Sutro Biopharma, Inc.

Zacks Investment Research - 5 months ago

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -1.69% and 7.66%, respectively, for the quarter ended June 2020.

Zacks Investment Research - 5 months ago

Sutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Benzinga - 5 months ago

Sutro Biopharma (NASDAQ: STRO) shares are trading lower on Thursday after Wells Fargo initiated coverage on the stock with an Overweight rating and an $18 price target.

PRNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., June 22, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicati...

PRNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., June 9, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicatio...

The Motley Fool - 7 months ago

These four cancer therapeutics stocks are poised to experience long-term growth. An investment in any of these today could bring huge rewards.

Other stocks mentioned: AGIO, JNCE, MRSN
PRNewsWire - 7 months ago

SAN FRANCISCO, May 21, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise p...

PRNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., May 21, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the applicatio...

PRNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., May 14, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its ...

Seeking Alpha - 8 months ago

Sutro Biopharma: Revenue-Generating Platform Positioned For Growth

Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor Sutro Biopharma

Zacks Investment Research - 9 months ago

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 16.88% and 21.22%, respectively, for the quarter ended December 2019.

Seeking Alpha - 11 months ago

Sutro Biopharma's Platform Technology Makes It A Promising Oncology Pick For 2020

About STRO

Sutro Biopharma operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and... [Read more...]

Industry
Biotechnology
IPO Date
Sep 27, 2018
CEO
William Newell
Employees
182
Stock Exchange
NASDAQ
Ticker Symbol
STRO
Full Company Profile

Financial Performance

In 2019, STRO's revenue was $42.74 million, an increase of 11.24% compared to the previous year's $38.42 million. Losses were -$55.74 million, 57.8% more than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for STRO stock is "Strong Buy." The 12-month stock price forecast is 28.57, which is an increase of 7.24% from the latest price.

Price Target
$28.57
(7.24% upside)
Analyst Consensus: Strong Buy